-
J.
Braun,
A.
Deodhar,
R.
Landewé,
X.
Baraliakos,
C.
Miceli-Richard,
J.
Sieper,
E.
Quebe‐Fehling,
R.
Martin,
B.
Porter,
K.
Gandhi,
D.
Heijde
(2018)
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
RMD Open, 4
-
J.
Sieper,
D.
Heijde,
M.
Dougados,
W.
Maksymowych,
B.
Scott,
J.
Boice,
Y.
Berd,
G.
Bergman,
S.
Curtis,
A.
Tzontcheva,
S.
Huyck,
H.
Weng
(2015)
A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis
Arthritis & Rheumatology (Hoboken, N.j.), 67
-
X.
Baraliakos,
J.
Listing,
J.
Brandt,
M.
Rudwaleit,
J.
Sieper,
J.
Braun
(2005)
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
Arthritis Research & Therapy, 7
-
(2017)
Axial spondyloarthritis
, 390
-
(2019)
TICOSPA: treat to target trial in axial spondylo arthritis: tight control in spondyloarthritis
-
L.
Coates,
A.
Moverley,
L.
McParland,
Sarah
Brown,
N.
Navarro-Coy,
J.
O’Dwyer,
D.
Meads,
P.
Emery,
P.
Conaghan,
P.
Helliwell
(2014)
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial
The Lancet, 386
-
D.
Baeten,
J.
Sieper,
J.
Braun,
X.
Baraliakos,
M.
Dougados,
P.
Emery,
A.
Deodhar,
B.
Porter,
R.
Martin,
M.
Andersson,
S.
Mpofu,
H.
Richards
(2015)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
The New England journal of medicine, 373 26
-
Jun
Park,
H.
Kwon,
J.
Park,
J.
Choi,
E.
Lee,
Y.
Song,
E.
Lee
(2016)
Impact of Dose Tapering of Tumor Necrosis Factor Inhibitor on Radiographic Progression in Ankylosing Spondylitis
PLoS ONE, 11
-
D.
Heijde,
A.
Deodhar,
J.
Wei,
E.
Drescher,
D.
Fleishaker,
T.
Hendrikx,
David
Li,
S.
Menon,
K.
Kanik
(2016)
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
Annals of the Rheumatic Diseases, 76
-
(2019)
A study treating participants with early axial spondyloarthritis (axSpA) taking an intense treatment approach versus routine treatment
-
R.
Inman,
John
Davis,
D.
Heijde,
L.
Diekman,
J.
Sieper,
Sung
Kim,
M.
Mack,
John
Han,
S.
Visvanathan,
Zhenhua
Xu,
B.
Hsu,
A.
Beutler,
J.
Braun
(2008)
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.
Arthritis and rheumatism, 58 11
-
Ho
Chung,
Pedro
Machado,
D.
Heijde,
M.
D'Agostino,
M.
Dougados
(2011)
Clinical and epidemiological research
-
J.
Braun,
X.
Baraliakos,
A.
Deodhar,
D.
Baeten,
J.
Sieper,
P.
Emery,
A.
Readie,
R.
Martin,
S.
Mpofu,
H.
Richards
(2016)
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
Annals of the Rheumatic Diseases, 76
-
P.
Meglio,
A.
Cesare,
U.
Laggner,
Chung-Ching
Chu,
L.
Napolitano,
F.
Villanova,
I.
Tosi,
F.
Capon,
R.
Trembath,
K.
Peris,
F.
Nestle
(2011)
The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans
PLoS ONE, 6
-
A.
Giardina,
A.
Ferrante,
F.
Ciccia,
R.
Impastato,
M.
Miceli,
A.
Principato,
G.
Triolo
(2010)
A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis
Rheumatology International, 30
-
R.
Landewé,
J.
Braun,
A.
Deodhar,
M.
Dougados,
W.
Maksymowych,
P.
Mease,
J.
Reveille,
M.
Rudwaleit,
D.
Heijde,
C.
Stach,
B.
Hoepken,
A.
Fichtner,
G.
Coteur,
M.
Longueville,
J.
Sieper
(2013)
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
Annals of the Rheumatic Diseases, 73
-
C.
Jandus,
G.
Bioley,
J.
Rivals,
J.
Dudler,
D.
Speiser,
P.
Romero
(2008)
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides.
Arthritis and rheumatism, 58 8
-
X.
Baraliakos,
H.
Haibel,
J.
Listing,
J.
Sieper,
J.
Braun
(2013)
Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis
Annals of the Rheumatic Diseases, 73
-
E.
Toussirot
(2018)
Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis
Expert Opinion on Biological Therapy, 18
-
The 2 randomized clinical trials demonstrating the efficacy of a secukinumab, an IL-17A inhibitor
-
X.
Baraliakos,
U.
Kiltz,
S.
Peters,
H.
Appel,
F.
Dybowski,
M.
Igelmann,
L.
Kalthoff,
D.
Krause,
Hans-Juergen
Menne,
Ertan
Saracbasi-Zender,
E.
Schmitz-Bortz,
Mathura
Vigneswaran,
J.
Braun
(2017)
Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis
Rheumatology, 56
-
A.
Sepriano,
A.
Regel,
D.
Heijde,
J.
Braun,
X.
Baraliakos,
R.
Landewé,
F.
Bosch,
L.
Falzon,
S.
Ramiro
(2017)
Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis
RMD Open, 3
-
The first study that suggested an efficacy of continuous NSAID administration in slowering disease progression in AS
-
J.
Sieper,
J.
Listing,
D.
Poddubnyy,
I.
Song,
K.
Hermann,
J.
Callhoff,
U.
Syrbe,
J.
Braun,
M.
Rudwaleit
(2015)
Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)
Annals of the Rheumatic Diseases, 75
-
M.
Rudwaleit,
D.
Heijde,
R.
Landewé,
J.
Listing,
N.
Akkoç,
J.
Brandt,
Jürgen
Braun,
C.
Chou,
E.
Collantes-Estévez,
M.
Dougados,
F.
Huang,
J.
Gu,
M.
Khan,
Y.
Kirazlı,
W.
Maksymowych,
H.
Mielants,
I.
Sørensen,
S.
Ozgoçmen,
E.
Roussou,
R.
Valle-Oñate,
U.
Weber,
J.
Wei,
J.
Sieper
(2009)
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
Annals of the Rheumatic Diseases, 68
-
J.
Sherlock,
B.
Joyce-Shaikh,
S.
Turner,
C.
Chao,
M.
Sathe,
J.
Grein,
D.
Gorman,
E.
Bowman,
T.
Mcclanahan,
J.
Yearley,
G.
Eberl,
C.
Buckley,
R.
Kastelein,
R.
Pierce,
D.
Laface,
D.
Cua
(2012)
IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells
Nature Medicine, 18
-
L.
Maxwell,
J.
Zochling,
A.
Boonen,
J.
Singh,
Mirella
Veras,
Elizabeth
Ghogomu,
Maria
Jandu,
P.
Tugwell,
G.
Wells
(2015)
TNF-alpha inhibitors for ankylosing spondylitis.
The Cochrane database of systematic reviews, 4
-
S.
Linden,
H.
Valkenburg,
A.
Cats
(1984)
Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.
Arthritis and rheumatism, 27 4
-
A.
Wanders,
D.
Heijde,
R.
Landewé,
Jéhan-Michel
Béhier,
A.
Calin,
I.
Olivieri,
H.
Zeidler,
M.
Dougados
(2005)
Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial.
Arthritis and rheumatism, 52 6
-
X.
Baraliakos,
B.
Borah,
J.
Braun,
D.
Baeten,
D.
Laurent,
J.
Sieper,
P.
Emery,
I.
McInnes,
J.
Laar,
P.
Wordsworth,
J.
Wollenhaupt,
H.
Kellner,
L.
Colin,
F.
Vandenhende,
K.
Radford,
W.
Hueber
(2015)
Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study
Annals of the Rheumatic Diseases, 75
-
F.
Kroon,
L.
Burg,
S.
Ramiro,
R.
Landewé,
R.
Buchbinder,
L.
Falzon,
D.
Heijde
(2015)
Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).
The Cochrane database of systematic reviews, 7
-
N.
Barkham,
H.
Keen,
L.
Coates,
P.
O'connor,
E.
Hensor,
A.
Fraser,
L.
Cawkwell,
A.
Bennett,
D.
McGonagle,
P.
Emery
(2009)
Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis.
Arthritis and rheumatism, 60 4
-
X.
Baraliakos,
W.
Maksymowych
(2016)
Imaging in the diagnosis and management of axial spondyloarthritis.
Best practice & research. Clinical rheumatology, 30 4
-
Runsheng
Wang,
A.
Dasgupta,
M.
Ward
(2015)
Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials
Annals of the Rheumatic Diseases, 75
-
J.
Závada,
M.
Uher,
K.
Sisol,
Š.
Forejtová,
K.
Jarošová,
H.
Mann,
J.
Vencovský,
K.
Pavelka
(2014)
A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study
Annals of the Rheumatic Diseases, 75
-
J.
Braun,
X.
Baraliakos,
J.
Listing,
C.
Fritz,
R.
Alten,
G.
Burmester,
Andreas
Krause,
S.
Schewe,
M.
Schneider,
H.
Sörensen,
H.
Zeidler,
J.
Sieper
(2007)
Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response
Annals of the Rheumatic Diseases, 67
-
D.
Heijde,
B.
Dijkmans,
P.
Geusens,
J.
Sieper,
K.
DeWoody,
P.
Williamson,
J.
Braun
(2005)
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
Arthritis and rheumatism, 52 2
-
J.
Sieper,
R.
Landewé,
M.
Rudwaleit,
D.
Heijde,
M.
Dougados,
P.
Mease,
J.
Braun,
A.
Deodhar,
A.
Kivitz,
Jessica
Walsh,
B.
Hoepken,
T.
Nurminen,
W.
Maksymowych
(2015)
Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
Arthritis & Rheumatology (Hoboken, N.j.), 67
-
Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers
-
John
Davis,
D.
Heijde,
J.
Braun,
M.
Dougados,
J.
Cush,
D.
Clegg,
A.
Kivitz,
R.
Fleischmann,
R.
Inman,
W.
Tsuji
(2003)
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Arthritis and rheumatism, 48 11
-
• One study showing the potential impact of TNFi on disease progression in AS
-
P.
Miossec
(2017)
Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice
RMD Open, 3
-
D.
Heijde,
R.
Landewé,
X.
Baraliakos,
H.
Houben,
A.
Tubergen,
P.
Williamson,
Weichun
Xu,
D.
Baker,
N.
Goldstein,
J.
Braun
(2008)
Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.
Arthritis and rheumatism, 58 10
-
A.
Deodhar,
L.
Gensler,
J.
Sieper,
M.
Clark,
C.
Calderon,
Yuhua
Wang,
Yiying
Zhou,
J.
Leu,
K.
Campbell,
K.
Sweet,
D.
Harrison,
E.
Hsia,
D.
Heijde
(2018)
Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Arthritis & Rheumatology, 71
-
D.
Heijde,
A.
Kivitz,
M.
Schiff,
J.
Sieper,
B.
Dijkmans,
J.
Braun,
M.
Dougados,
J.
Reveille,
R.
Wong,
H.
Kupper,
John
Davis
(2006)
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
Arthritis and rheumatism, 54 7
-
M.
Dougados,
D.
Heijde,
J.
Sieper,
J.
Braun,
W.
Maksymowych,
G.
Citera,
C.
Miceli-Richard,
J.
Wei,
R.
Pedersen,
R.
Bonin,
Mahboob
Rahman,
I.
Logeart,
J.
Wajdula,
A.
Koenig,
B.
Vlahos,
D.
Alvarez,
J.
Bukowski
(2014)
Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial
Arthritis & Rheumatology, 66
-
M.
Rudwaleit,
J.
Listing,
J.
Brandt,
Jürgen
Braun,
J.
Sieper
(2004)
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis
Annals of the Rheumatic Diseases, 63
-
A.
Deodhar,
D.
Poddubnyy,
C.
Pacheco-Tena,
C.
Salvarani,
E.
Lespessailles,
P.
Rahman,
P.
Järvinen,
J.
Sánchez-Bursón,
K.
Gaffney,
E.
Lee,
E.
Krishnan,
Silvia
Santisteban,
Xiaoqi
Li,
F.
Zhao,
H.
Carlier,
J.
Reveille
(2019)
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
Arthritis & Rheumatology (Hoboken, N.j.), 71
-
G.
Bakland,
J.
Gran,
J.
Nossent
(2011)
Increased mortality in ankylosing spondylitis is related to disease activity
Annals of the Rheumatic Diseases, 70
-
D.
Heijde,
J.
Wei,
M.
Dougados,
P.
Mease,
A.
Deodhar,
W.
Maksymowych,
F.
Bosch,
J.
Sieper,
T.
Tomita,
R.
Landewé,
F.
Zhao,
E.
Krishnan,
D.
Adams,
B.
Pangallo,
H.
Carlier,
M.
Churchill,
K.
Flint,
G.
Gladstein,
M.
Greenwald,
Mary
Howell,
A.
Ince,
J.
Kaine,
D.
Mehta,
Eric
Peters,
R.
Querubin,
J.
Reveille,
Richard
Roseff,
R.
Diegel,
Christine
Thai,
L.
Bessette,
F.
Morin,
P.
Rahman,
Aa
Rodriguez,
F.
Cons-Molina,
S.
Barragan,
Cassandra
Skinner,
C.
Tena,
César
Remus,
J.
Rodriguez,
Seung-Jae
Hong,
Yeon-Ah
Lee,
J.
Ju,
S.
Kang,
Tae-Hwan
Kim,
Chang-Keun
Lee,
E.
Lee,
Sang
Lee,
Min-Chan
Park,
K.
Shin,
Sang-Hoon
Lee,
Hung-An
Chen,
Ying-Chou
Chen,
S.
Hsieh,
J.
Lan,
Z.
Dvořák,
R.
Moravcová,
Martina
Malcova,
Y.
Taniguchi,
M.
Kishimoto,
K.
Tada,
H.
Dobashi,
K.
Inui,
Y.
Ueki,
Y.
Matsumoto,
Y.
Koyama,
K.
Hatta,
T.
Atsumi,
H.
Goto,
K.
Matsui,
Y.
Takakubo,
G.
Neeck,
D.
Poddubnyy,
A.
Rubbert-Roth,
M.
Szymańska,
T.
Blicharski,
A.
Dudek,
A.
Racewicz,
R.
Wojciechowski,
M.
Sande,
E.
Griep,
M.
Nurmohamed,
G.
Matsievskaya,
E.
Shmidt,
M.
Stanislav,
S.
Yakushin,
O.
Ershova,
A.
Rebrov,
T.
Balazs,
R.
Cseuz,
E.
Drescher,
G.
Poór
(2018)
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and
The Lancet, 392
-
D.
Baeten,
X.
Baraliakos,
J.
Braun,
J.
Sieper,
P.
Emery,
D.
Heijde,
I.
McInnes,
J.
Laar,
R.
Landewé,
P.
Wordsworth,
J.
Wollenhaupt,
H.
Kellner,
J.
Paramarta,
Jiawei
Wei,
A.
Brachat,
S.
Bek,
D.
Laurent,
Yali
Li,
Ying
Wang,
A.
Bertolino,
S.
Gsteiger,
A.
Wright,
W.
Hueber
(2013)
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
The Lancet, 382
-
J.
Sieper,
D.
Heijde,
M.
Dougados,
P.
Mease,
W.
Maksymowych,
M.
Brown,
V.
Arora,
A.
Pangan
(2012)
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
Annals of the Rheumatic Diseases, 72
-
F.
Kroon,
R.
Landewé,
M.
Dougados,
D.
Heijde
(2012)
Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis
Annals of the Rheumatic Diseases, 71
-
complete overview of the current drug management of axSpA
-
N.
Haroon,
R.
Inman,
T.
Learch,
M.
Weisman,
Minjae
Lee,
M.
Rahbar,
M.
Ward,
J.
Reveille,
L.
Gensler
(2013)
The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis.
Arthritis and rheumatism, 65 10
-
M.
Yates,
Louise
Hamilton,
F.
Elender,
L.
Dean,
H.
Doll,
A.
Macgregor,
Joegi
Thomas,
K.
Gaffney
(2015)
Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial
The Journal of Rheumatology, 42
-
D.
Heijde,
R.
Landewé,
S.
Einstein,
P.
Ory,
D.
Vosse,
L.
Ni,
Shao-Lee
Lin,
W.
Tsuji,
John
Davis
(2008)
Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept.
Arthritis and rheumatism, 58 5
-
F.
Cantini,
L.
Niccoli,
E.
Cassarà,
O.
Kaloudi,
C.
Nannini
(2013)
Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study
Biologics : Targets & Therapy, 7
-
D.
Heijde,
S.
Ramiro,
R.
Landewé,
X.
Baraliakos,
F.
Bosch,
A.
Sepriano,
A.
Regel,
A.
Ciurea,
H.
Dagfinrud,
M.
Dougados,
F.
Gaalen,
P.
Géher,
I.
Horst-Bruinsma,
R.
Inman,
Merryn
Jongkees,
U.
Kiltz,
T.
Kvien,
P.
Machado,
H.
Marzo-Ortega,
A.
Moltó,
V.
Navarro-Compán,
S.
Ozgoçmen,
F.
Pimentel-Santos,
J.
Reveille,
M.
Rudwaleit,
J.
Sieper,
P.
Sampaio-Barros,
D.
Wiek,
J.
Braun
(2017)
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Annals of the Rheumatic Diseases, 76
-
M.
Rudwaleit,
S.
Schwarzlose,
E.
Hilgert,
J.
Listing,
J.
Braun,
J.
Sieper
(2007)
MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis
Annals of the Rheumatic Diseases, 67
-
M.
Ward,
A.
Deodhar,
E.
Akl,
A.
Lui,
J.
Ermann,
L.
Gensler,
Judith
Smith,
D.
Borenstein,
J.
Hiratzka,
P.
Weiss,
R.
Inman,
V.
Majithia,
N.
Haroon,
W.
Maksymowych,
J.
Joyce,
B.
Clark,
R.
Colbert,
M.
Figgie,
D.
Hallegua,
P.
Prete,
J.
Rosenbaum,
Judith
Stebulis,
F.
Bosch,
D.
Yu,
Amy
Miller,
J.
Reveille,
L.
Caplan
(2016)
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Arthritis & Rheumatology, 68
-
H.
Appel,
R.
Maier,
P.
Wu,
R.
Scheer,
A.
Hempfing,
R.
Kayser,
A.
Thiel,
Andreas
Radbruch,
C.
Loddenkemper,
J.
Sieper
(2011)
Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response
Arthritis Research & Therapy, 13
-
J.
Sieper,
D.
Poddubnyy
(2016)
New evidence on the management of spondyloarthritis
Nature Reviews Rheumatology, 12
-
J.
Smolen,
Monika
Schöls,
J.
Braun,
M.
Dougados,
O.
FitzGerald,
D.
Gladman,
A.
Kavanaugh,
R.
Landewé,
P.
Mease,
J.
Sieper,
T.
Stamm,
M.
Wit,
D.
Aletaha,
X.
Baraliakos,
N.
Betteridge,
F.
Bosch,
L.
Coates,
P.
Emery,
L.
Gensler,
L.
Gossec,
P.
Helliwell,
Merryn
Jongkees,
T.
Kvien,
R.
Inman,
I.
McInnes,
M.
Maccarone,
P.
Machado,
A.
Moltó,
A.
Ogdie,
D.
Poddubnyy,
C.
Ritchlin,
M.
Rudwaleit,
A.
Tanew,
B.
Thio,
D.
Veale,
K.
Vlam,
D.
Heijde
(2017)
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Annals of the Rheumatic Diseases, 77
-
J.
Sieper,
T.
Klopsch,
M.
Richter,
A.
Kapelle,
M.
Rudwaleit,
Sabine
Schwank,
E.
Regourd,
Michael
May
(2007)
Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study
Annals of the Rheumatic Diseases, 67
-
H.
Marzo-Ortega,
J.
Sieper,
A.
Kivitz,
R.
Blanco,
Martin
Cohen,
E.
Delicha,
Susanne
Rohrer,
H.
Richards
(2017)
Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2
RMD Open, 3
-
B.
Noureldin,
N.
Barkham
(2018)
The current standard of care and the unmet needs for axial spondyloarthritis
Rheumatology (Oxford, England), 57
-
Christoph
Molnar,
A.
Scherer,
X.
Baraliakos,
M.
Hooge,
R.
Micheroli,
P.
Exer,
R.
Kissling,
G.
Tamborrini,
L.
Wildi,
M.
Nissen,
P.
Zufferey,
J.
Bernhard,
U.
Weber,
R.
Landewé,
D.
Heijde,
A.
Ciurea
(2017)
TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort
Annals of the Rheumatic Diseases, 77
-
(2012)
Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort
, 71
-
J.
Taurog,
A.
Chhabra,
R.
Colbert
(2016)
Ankylosing Spondylitis and Axial Spondyloarthritis.
The New England journal of medicine, 374 26
-
J.
Sieper,
A.
Deodhar,
H.
Marzo-Ortega,
J.
Aelion,
R.
Blanco,
Tseng
Jui-Cheng,
M.
Andersson,
B.
Porter,
H.
Richards
(2016)
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
Annals of the Rheumatic Diseases, 76
-
N.
Yeremenko,
J.
Paramarta,
D.
Baeten
(2014)
The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis
Current Opinion in Rheumatology, 26
-
I.
Song,
D.
Poddubnyy,
M.
Rudwaleit,
J.
Sieper
(2008)
Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs.
Arthritis and rheumatism, 58 4
-
•• The updated European recommendations for the treatment of axSpA
-
Jennifer
Anderson,
G.
Baron,
D.
Heijde,
D.
Felson,
M.
Dougados
(2001)
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis.
Arthritis and rheumatism, 44 8
-
D.
Heijde,
E.
Lie,
T.
Kvien,
J.
Sieper,
F.
Bosch,
J.
Listing,
J.
Braun,
R.
Landewé
(2008)
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis
Annals of the Rheumatic Diseases, 68
-
E.
Toussirot
(2012)
The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
Inflammation & allergy drug targets, 11 2
-
J.
Sieper,
J.
Lenaerts,
J.
Wollenhaupt,
M.
Rudwaleit,
Mazurov
Vi,
L.
Myasoutova,
S.
Park,
Y.
Song,
R.
Yao,
D.
Chitkara,
N.
Vastesaeger
(2013)
Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1
Annals of the Rheumatic Diseases, 73
-
W.
Hueber,
B.
Sands,
S.
Lewitzky,
M.
Vandemeulebroecke,
W.
Reinisch,
P.
Higgins,
J.
Wehkamp,
B.
Feagan,
M.
Yao,
M.
Karczewski,
J.
Karczewski,
N.
Pezous,
S.
Bek,
G.
Bruin,
Bjoern
Mellgard,
C.
Berger,
M.
Londei,
A.
Bertolino,
G.
Tougas,
S.
Travis
(2012)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Gut, 61
-
(2019)
NCT02963506 a multicenter study to evaluate the efficacy and safety of different doses of bimekizumab in subjects with active ankylosing spondylitis
-
• The single study that demonstrated the usefulness of a tight control strategy in the field of spondyloarthritis
-
D.
Baeten,
M.
Østergaard,
J.
Wei,
J.
Sieper,
P.
Järvinen,
L.
Tam,
C.
Salvarani,
Tae-Hwan
Kim,
A.
Solinger,
Y.
Datsenko,
Chandrasena
Pamulapati,
S.
Visvanathan,
D.
Hall,
S.
Aslanyan,
P.
Scholl,
S.
Padula
(2018)
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Annals of the Rheumatic Diseases, 77
-
D.
Heijde,
D.
Salonen,
B.
Weissman,
R.
Landewé,
W.
Maksymowych,
H.
Kupper,
S.
Ballal,
E.
Gibson,
R.
Wong
(2009)
Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years
Arthritis Research & Therapy, 11
-
American recommendations for the management of AS and axSpA that are quite similar to the position of the european society
-
M.
Rudwaleit,
M.
Khan,
J.
Sieper
(2005)
The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?
Arthritis and rheumatism, 52 4
